-
Investors who purchased shares of Charles River Laboratories International, Inc. (NYSE: CRL) shares have certain options and should contact the Shareholders Foundation, Inc.
-
To have your information reviewed for options and to receive notifications about this investigation, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Investigation Overview
An investigation on behalf of investors in shares of Charles River Laboratories International, Inc. (NYSE: CRL) was announced over potential breaches of fiduciary duties by certain officers and directors at Charles River Laboratories.
The investigation by a law firm concerns whether certain Charles River Laboratories International, Inc. directors breached their fiduciary duties.
Wilmington, MA based Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. Charles River Laboratories International, Inc. reported that its annual Total Revenue rose from over $1.68 billion in 2016 to over $1.85 billion in 2017 and that its Net Income declined from $156.36 million in 2016 to $125.44 million in 2017.
Shares of Charles River Laboratories International, Inc. (NYSE: CRL) rose from $67.20 per share in October 2016 to as high as $119.05 per share in October 2017.
